New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients
13 nov. 2023 08h00 HE
|
Daxor Corporation
Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood...
Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume
09 nov. 2023 08h00 HE
|
Daxor Corporation
Patent Covers Novel Optimization of Care by Remote Monitoring Devices Including Smartwatches Oak Ridge, TN, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...
Expert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
13 oct. 2023 08h00 HE
|
Daxor Corporation
Leading Clinicians Highlight Significant Outcome Improvements with Daxor’s Blood Volume Analysis Innovative Technology Oak Ridge, TN, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq:...
New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
11 oct. 2023 08h00 HE
|
Daxor Corporation
Blood Volume Analysis (BVA) in 83-Patient Study Provided Highly Effective Guidance for Care of Heart Failure Patients Otherwise Unavailable Using Common Proxy Diagnostic Methods Oak Ridge, TN, Oct. ...
Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
04 oct. 2023 08h00 HE
|
Daxor Corporation
Support for Development of Daxor’s Non-Nuclear Tracer for Next Generation Blood Volume Analyzer Systems Aims to Deliver Gold Standard Accuracy with Increased Access, Ease of Use, and Frequency of...
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023
27 sept. 2023 08h00 HE
|
Daxor Corporation
Daxor’s Blood Volume Technology Featured at Scientific Session Oak Ridge, TN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement...
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
26 sept. 2023 08h00 HE
|
Daxor Corporation
The Premier Event for The Cardiovascular Industry's Leading Network of Executives and Clinicians - Transforming Cardiovascular Care Through Sharing Best Practices and Organizational Performance...
Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients
11 sept. 2023 12h00 HE
|
Daxor Corporation
Oak Ridge, TN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the National Institutes of Health...
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 09h15 HE
|
Daxor Corporation
Oak Ridge, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
28 août 2023 16h15 HE
|
Daxor Corporation
Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...